Edwards Lifesciences Corporation
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | $822.3M | $2.62B | $930.1M |
| FY2017 | $438.4M | $2.96B | $818.3M |
| FY2018 | $593.8M | $3.14B | $714.1M |
| FY2019 | $594.4M | $4.15B | $1.18B |
| FY2020 | $595.0M | $4.57B | $1.18B |
| FY2021 | $595.7M | $5.84B | $862.8M |
| FY2022 | $596.3M | $5.81B | $769.0M |
| FY2023 | $597.0M | $6.65B | $1.13B |
| FY2024 | $597.7M | $10.00B | $3.05B |
| FY2025 | $598.3M | $10.34B | $2.94B |